Pharma still heavily investing in UK R&D despite Brexit

Pharma reacts to Brexit vote delay
Credit: cbies

The pharmaceutical industry continues to significantly invest in UK research and development despite the future uncertainty of Brexit, according to data from the ABPI.

The data shows industry spent £370.9 million on partnerships relating to research and development activities in the UK during 2017 – a 9.7% increase on 2016.

Spending on R&D activities accounts for three quarters of the total spending disclosed on the database for working in partnership with leading UK health experts and organisations to improve patient care.

“It is an encouraging testament to the pharmaceutical industry’s commitment to the UK as a hub of science and innovation that, in the wake of Brexit uncertainty, it continues to invest significantly in research and development as shown in this latest disclosure data,” said ABPI Chief Exec Mike Thompson.

“£370 million spent on partnerships with leading healthcare experts and organisations on scientific discovery of life-enhancing medicines cements our place as a scientific hub which must be retained alongside continued cooperation on the regulation, trade and supply of medicines, after Brexit.”